SEC Form SC 13G filed by Replimune Group Inc.

2/9/24 12:09:28 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $REPL alert in real time by email

SC 13G 1 ReplimuneGroupREPL.txt MS INITIAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Replimune Group, Inc. ----------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------- (Title of Class of Securities) 76029N106 ----------------------------------------------------- (CUSIP Number) December 31, 2023 ----------------------------------------------------- (Date Of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1745 (3-06) CUSIP No.76029N106 13G Page 2 of 5 Pages -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON: I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: Morgan Stanley I.R.S. # 36-3145972 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY: -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware. -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER: SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER: EACH 4,387,672 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER: WITH: 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER: 4,388,888 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 4,388,888 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES: [ ] -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 7.4% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON: HC, CO -------------------------------------------------------------------------------- CUSIP No.76029N106 13G Page 3 of 5 Pages -------------------------------------------------------------------------------- Item 1. (a) Name of Issuer: Replimune Group, Inc. -------------------------------------------------------------- (b) Address of Issuer's Principal Executive Offices: 500 UNICORN PARK WOBURN MA 01801 UNITED STATES OF AMERICA -------------------------------------------------------------- Item 2. (a) Name of Person Filing: (1) Morgan Stanley -------------------------------------------------------------- (b) Address of Principal Business Office, or if None, Residence: (1) 1585 Broadway New York, NY 10036 -------------------------------------------------------------- (c) Citizenship: (1) Delaware. -------------------------------------------------------------- (d) Title of Class of Securities: Common Stock -------------------------------------------------------------- (e) CUSIP Number: 76029N106 -------------------------------------------------------------- Item 3. If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [ ] An investment adviser in accordance with Sections 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) [x] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] A non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J); (k) [ ] Group, in accordance with sections 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with sections 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not Applicable CUSIP No.76029N106 13G Page 4 of 5 Pages -------------------------------------------------------------------------------- Item 4. Ownership as of December 31, 2023.* (a) Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s). (b) Percent of Class: See the response(s) to Item 11 on the attached cover page(s). (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s). (ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s). (iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s). (iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s). Item 5. Ownership of Five Percent or Less of a Class. Not Applicable Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Not Applicable Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8. Identification and Classification of Members of the Group. Not Applicable Item 9. Notice of Dissolution of Group. Not Applicable Item 10. Certification. (1) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release. CUSIP No.76029N106 13G Page 5 of 5 Pages -------------------------------------------------------------------------------- Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 09, 2024 Signature: /s/ Christopher O'Hara -------------------------------------------------------------------- Name/Title: Christopher O'Hara/Authorized Signatory, Morgan Stanley -------------------------------------------------------------------- MORGAN STANLEY

Get the next $REPL alert in real time by email

Date	Price Target	Rating	Analyst
8/28/2024	$17.00	Buy	ROTH MKM
4/17/2023	$44.00	Overweight	Piper Sandler
11/19/2021	$52.00	Overweight	Piper Sandler
10/15/2021	$60.00	Buy	BTIG Research
8/23/2021	$55.00 → $49.00	Outperform	SVB Leerink
8/9/2021	$56.00 → $55.00	Outperform	SVB Leerink

SEC Form SC 13G filed by Replimune Group Inc.

Chat with this insight

Recent Analyst Ratings for $REPL

$REPL Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

$REPL Leadership Updates

Live Leadership Updates

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

Tessellate BIO Emerges from Stealth

Replimune Announces Appointment of Emily Hill as Chief Financial Officer

$REPL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Balachandran Madhavan

SEC Form 3 filed by new insider Balachandran Madhavan

Executive Chairman Astley-Sparke Philip gifted 50,000 shares, decreasing direct ownership by 3% to 1,437,350 units (SEC Form 4)

$REPL Financials

Live finance-specific insights

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update

$REPL Market Insights

Live Market Insights

Replimune shares are trading higher after the company announced a private placement financing with an institutional investor for gross proceeds of approximately $100 million.

Replimune Announces Private Placement Financing With An Institutional Investor For Gross Proceeds Of ~$100M

Barclays Maintains Overweight on Replimune Group, Raises Price Target to $17

$REPL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

ROTH MKM initiated coverage on Replimune with a new price target

Piper Sandler resumed coverage on Replimune with a new price target

Piper Sandler initiated coverage on Replimune Group with a new price target

$REPL SEC Filings

$REPL Press Releases

Fastest customizable press release news feed in the world

SEC Form S-8 filed by Replimune Group Inc.

Replimune Group Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form EFFECT filed by Replimune Group Inc.

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Analyst Ratings for
$REPL

$REPL
Large Ownership Changes

$REPL
Leadership Updates

$REPL
Insider Trading

$REPL
Financials

$REPL
Market Insights

$REPL
Analyst Ratings

$REPL
SEC Filings

$REPL
Press Releases